Workflow
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
APLSApellis(APLS) Newsfilter·2024-02-27 20:05

Generated 397millioninfullyear2023revenues,including397 million in full year 2023 revenues, including 275 million for SYFOVRE® (pegcetacoplan injection) and 91millionforEMPAVELI®(pegcetacoplan)StrongSYFOVRElaunch,withmorethan160,000totaldoses(commercialandsamples)distributedin2023ToplinedatafromPhase3VALIANTstudyofsystemicpegcetacoplaninC3GandIC−MPGNexpectedinmid−2024Cashandcashequivalentsof91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 Topline data from Phase 3 VALIANT study of systemic pegcetacoplan in C3G and IC-MPGN expected in mid-2024Cash and cash equivalents of 351 million as of December 31, 2023 WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ...